TLR3 and neoplasm: Following these findings, a miR148a inhibitor, poly I:C (TLR3 agonist), and tumor antigen were then packaged together in a DC-based cationic polypeptide micelle nanovaccine, which promotes enhanced anti-tumor immunity and survival by expanding mature DCs and suppressing Treg and myeloid-derived suppressor cell (MDSC) development (150).